|
業務類別
|
Biotechnology |
|
業務概覽
|
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA"). |
| 公司地址
| 11 Great Valley Parkway, Malvern, PA, USA, 19355 |
| 電話號碼
| +1 484 328-4701 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ocugen.com |
| 員工數量
| 116 |
| Dr. Shankar Musunuri, M.B.A.,PhD |
Chairman of the Board and Chief Executive Officer |
美元 757.90K |
28/04/2026 |
| Ms. Treerita Essalima Johnson-Greene |
Chief Financial Officer and Principal Accounting Officer |
-- |
03/06/2026 |
| Dr. Mohamed Genead, M. Sc. |
Chief Medical Officer |
-- |
11/06/2026 |
|
|
| Mr. Blaise A. Coleman |
Independent Director |
28/04/2026 |
| Dr. Shankar Musunuri, M.B.A.,PhD |
Chairman of the Board and Chief Executive Officer |
28/04/2026 |
| Dr. Uday B. Kompella, PhD |
Independent Director |
28/04/2026 |
| Dr. Junge John Zhang, PhD |
Independent Director |
28/04/2026 |
| Ms. Kirsten Castillo, M.B.A. |
Independent Director |
28/04/2026 |
| Dr. Satish Chandran, PhD |
Independent Director |
28/04/2026 |
|
|
|
|
